Ekso Bionics Files Q3 2024 10-Q Report

TL;DR

Ekso Bionics Q3 10-Q filed. Check financials for latest performance.

AI Summary

Ekso Bionics Holdings, Inc. filed its Q3 2024 10-Q report on October 28, 2024, for the period ending September 30, 2024. The company's financial performance and operational details for this quarter are detailed within the filing. Specific financial figures and business developments are outlined in the report, providing insight into the company's current standing.

Why It Matters

This filing provides investors and stakeholders with the latest financial and operational performance data for Ekso Bionics, crucial for evaluating the company's trajectory in the exoskeleton technology market.

Risk Assessment

Risk Level: medium — As a company in a developing technological field, Ekso Bionics faces inherent risks related to market adoption, competition, and regulatory approvals.

Key Numbers

• 10,000 — Shares (Shares outstanding as of September 30, 2024.)
• 141,429 — Shares (Shares outstanding as of December 31, 2023.)
• 21,998 — Shares (Shares outstanding as of September 30, 2023.)
• 14,848 — Shares (Shares outstanding as of December 31, 2022.)

Key Players & Entities

• EKSO BIONICS HOLDINGS, INC. (company) — Filer
• 20240930 (date) — Period of Report
• 20241028 (date) — Filing Date
• 101 GLACIER POINT (address) — Business Address
• SAN RAFAEL (location) — Business City
• NV (state) — State of Incorporation

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share EKSO Nasdaq Cap
• $250 — nstitutions with each balance under the $250 Federal Deposit Insurance Corporation (
• $100 — posit insurance limits of approximately $100 at each of the Company's two foreign ba

Filing Documents

• ekso20240930_10q.htm (10-Q) — 1791KB
• ex_719122.htm (EX-31.1) — 13KB
• ex_719123.htm (EX-31.2) — 13KB
• ex_719124.htm (EX-32.1) — 6KB
• ex_719125.htm (EX-32.2) — 6KB
• 0001437749-24-032291.txt ( ) — 8587KB
• ekso-20240930.xsd (EX-101.SCH) — 71KB
• ekso-20240930_cal.xml (EX-101.CAL) — 39KB
• ekso-20240930_def.xml (EX-101.DEF) — 466KB
• ekso-20240930_lab.xml (EX-101.LAB) — 400KB
• ekso-20240930_pre.xml (EX-101.PRE) — 511KB
• ekso20240930_10q_htm.xml (XML) — 1608KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2024and 2023 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months ended September 30, 2024 and 2023(unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2024 and 2023 (unaudited) 8 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 5. Other Information 41 Item 6. Exhibits 42

Signatures

Signatures 43 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Ekso Bionics Holdings, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value) September 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and restricted cash $ 8,292 $ 8,638 Accounts receivable, net of allowances of $ 29 and $ 79 , respectively 6,964 5,645 Inventories 5,031 5,050 Prepaid expenses and other current assets 779 875 Total current assets 21,066 20,208 Property and equipment, net 1,628 2,018 Right-of-use assets 891 977 Intangible assets, net 4,662 4,892 Goodwill 431 431 Other assets 531 392 Total assets $ 29,209 $ 28,918 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,808 $ 1,847 Accrued liabilities 1,975 2,664 Deferred revenues, current 2,039 1,993 Notes payable, current 1,250 1,250 Lease liabilities, current 434 363 Total current liabilities 7,506 8,117 Deferred revenues 1,971 2,169 Notes payable, net 4,106 4,832 Lease liabilities 556 723 Warrant liabilities 35 366 Other non-current liabilities 165 105 Total liabilities 14,339 16,312 Commitments and Contingencies (Note 14) Stockholders' equity: Convertible preferred stock, $ 0.001 par value; 10,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value; 141,429 shares authorized; 21,998 and 14,848 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 22 15 Additional paid-in capital 261,898 251,580 Accumulated other comprehensive income 12 156 Accumulated deficit ( 247,062 ) ( 239,145 ) Total stockholders' equity 14,870 12,606 Total liabilities and stockholders' equity $ 29,209 $ 28,918 The accompanying notes are an integral part of these condensed consolidated financial statements 4 Table of Contents Ekso Bionics Holdings, Inc. Condensed Consolidated Statements of Operations and C

View Full Filing

View this 10-Q filing on SEC EDGAR